Cantor Fitzgerald downgraded Crispr Therapeutics (CRSP) to Neutral from Overweight after assuming coverage of the name. Crispr owns 40% of exa-cel, an ex vivo autologous cell therapy being developed by partner Vertex (VRTX), and Cantor expects exa-cel to become the leading therapy for sickle cell disorder, though it could take time to break down the many potential barriers to adoption, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Crispr Therapeutics proposes to elect Sandy Mahatme to board of directos
- CRISPR Therapeutics Proposes New Appointment to the Board of Directors
- Vertex Pharmaceuticals price target raised to $425 from $400 at BofA
- Biotech Alert: Searches spiking for these stocks today